Company Registry

Nami Therapeutics Corporation (AKA:Nami)
Profile last edited on: 5/4/2020

Specifically designed nanoparticles for targeted drug delivery.
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

Room 108 1392 Storrs Road
Storrs, CT 06268
   (914) 483-8886
Multiple Locations:   
Congressional District:   02
County:   Tolland

Public Profile

Currently resident in the Technology Incubation Program at the University of Connecticut, Nami Therapeutics Corporation personnel are structured around developing specifically designed nanoparticles for the targeted delivery of therapeutic agents, including radio-therapeutics, to tumors. Using technologies licensed from the University of Connecticut and the University of North Carolina, the Nami team are academics with over 50 years of collective experience in the drug delivery field. The objective is to advance the firm's nanotechnology-based products to the clinical trial stage by demonstrating the efficacy of its products in preclinical models, and by completing IND enabling activities such as manufacturing process development (CMC) and safety/toxicity assessments. A current product of focus is a tumor-specific radioactive therapy designed to specifically target peritoneal metastasis of ovarian cancer. Animal studies have shown that the platform offers increased efficacy and reduced toxicity as compared to other treatment options

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Xiuling Lu -- CEO

  Ruobing Xia -- President

  Michael Jay -- Chief Scientific Officer

  Ron Pion -- Clinical Advisor

  Andrew Salner -- Clinical Advisor

  David Worthen -- Head of R&D

SBIR firms in the news

There are no news available.